Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.
Obamacare's expansion of Medicaid is a boon for investors. But if you're hungry for market-beating growth, forgo the overvalued mega-cap health stocks.
The PE giant is reported to be leading the auction for the activist-pressured hospital staffing company and is likely to have bid approximately $4 billion.
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.
JNJ is off 2.3% on heavy trade and is taking out a very solid support zone in the process. This nasty breakdown has further to go.
The health care giant says it can access foreign cash by borrowing against it. But it has little use for price controls.
Analysts say UnitedHealthcare is an attractive stock after the company beat earnings expectations Tuesday, sending the stock price soaring.
J&J reiterates its full-year sales guidance of between $71.5 billion and $72.2 billion and says it sees full-year adjusted per-share earnings of between $6.68 and $6.73.
Shares of the insurance giant were slipping on a price-target cut and downgrade to neutral.
The feds assert that the firms' bickering will prove that predictions about the merger's benefits are bunk.
Johnson & Johnson is undergoing a transformation in its product portfolio. These three ETFs may benefit if investors are excited about third-quarter results.
There are reasons to be cautiously optimistic about Intuitive Surgical.
Most of the 11 S&P sectors have negative weekly charts. Here's this week's scorecard.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.